(Albany, US) DelveInsight has launched a new report on Hunter Syndrome Pipeline

 

“Hunter Syndrome Pipeline Insight, 2020” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Hunter Syndrome market. A detailed picture of the Hunter Syndrome pipeline landscape is provided, which includes the disease overview and Hunter Syndrome treatment guidelines. The assessment part of the report embraces in-depth Hunter Syndrome commercial assessment and clinical assessment of the Hunter Syndrome pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Hunter Syndrome collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

 

Hunter Syndrome, also known as Mucopolysaccharidosis type II (MPS II), I2S deficiency and Iduronate 2- sulfatase deficiency. It is an inherited disorder of carbohydrate metabolism that occurs almost exclusively in males. MPS II is caused by mutations in the IDS gene and is inherited in an X-linked manner. Females are generally unaffected carriers of this condition. As per National MPS Society, Hunter syndrome takes its name from Charles Hunter, the professor of medicine in Manitoba, Canada, who first described two brothers with the disease in 1917. MPS II has a wide range of symptoms that vary in severity and can be managed and treated with enzyme replacement therapies. There is no cure for MPS II and it affects 1 in 100,000 to 1 in 170,000 primarily males.

 

 

Request for free sample page: – https://www.delveinsight.com/sample-request/hunter-syndrome-pipeline-insight

 

Hunter Syndrome Pipeline Development Activities 

 The report provides insights into: 

• All of the companies that are developing therapies for the treatment of Hunter Syndrome with aggregate therapies developed by each company for the same.
• Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the Hunter Syndrome treatment.
• Hunter Syndrome key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of Hunter Syndrome market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university web sites and industry-specific third-party sources, etc.  

 

Hunter Syndrome Pipeline

 

The dynamics of Hunter syndrome market is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the disease, incremental healthcare spending across the world, and expected the launch of emerging therapies during the forecast period of 2020–2030. Companies like JCR Pharmaceuticals (JR-141), Green Cross Corporation (GC1111B or Hunterase), Regenxbio Inc. (RGX-121), and others are working toward the development of new treatment therapies for Hunter syndrome. While some of the companies have recently shifted their focus toward this indication, whereas others are expected to create a significant influence on the market size during the forecast period.

 

JR-141 (JCR Pharmaceuticals) is a blood-brain-barrier penetrating therapeutic enzyme for Hunter syndrome currently undergoing one Phase III (Japan) and one Phase II (Brazil) clinical trials. In March 2018, JR-141 was designated under the SAKIGAKE Designation System in Japan by the Ministry of Health, Labour and Welfare, and is planning to apply for marketing approval in 2020. It has also received Orphan Drug Designation from both the EMA and the FDA.

 

Marketed drug included in the report

• Elaprase: Shire

 

Emerging included in the report

• JR-141: JCR Pharmaceuticals
• GC1111B or Hunterase: Green Cross Corporation
• RGX-121: Regenxbio Inc.

 

Hunter Syndrome Report Scope

• The Hunter Syndrome report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Hunter Syndrome across the complete product development cycle, including all clinical and nonclinical stages.
• It comprises of detailed profiles of Hunter Syndrome therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
• Detailed Hunter Syndrome research and development progress and trial details, results wherever available, are also included in the pipeline study.
• Coverage of dormant and discontinued pipeline projects along with the reasons if available across Hunter Syndrome

 

Download free sample page: – https://www.delveinsight.com/sample-request/hunter-syndrome-pipeline-insight

 

Table of content

1. Report Introduction

2. Hunter Syndrome 

3. Hunter Syndrome Current Treatment Patterns

4. Hunter Syndrome – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Hunter Syndrome Late Stage Products (Phase-III)

7. Hunter Syndrome Mid Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Hunter Syndrome Discontinued Products

13. Hunter Syndrome Product Profiles

14. Hunter Syndrome Key Companies

15. Hunter Syndrome Key Products

16. Dormant and Discontinued Products

17. Hunter Syndrome Unmet Needs

18. Hunter Syndrome Future Perspectives

19. Hunter Syndrome Analyst Review  

20. Appendix

21. Report Methodology

 

Related Reports

 

 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/